When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Baxter's IV plant in North Carolina was flooded by Hurricane Helene. That plant provides 60% of the U.S. supply of IV bags. 

Early data suggest the drug, an oral lipoprotein (a) disruptor, could make a significant impact on patient care. AstraZeneca will pay $100 million upfront, with much more to follow if certain milestones are met. 

Some of Medtronic's 600 and 700 series MiniMed insulin pumps are experiencing significant battery issues when dropped, bumped or impacted in any way. This has been linked to reports of health issues in more than 180 patients.

Millions of heart failure patients who qualify for standard medical therapies do not receive treatment due to poor health literacy, limited access to care and medication costs.

“Unlike expensive pharmaceuticals like Ozempic, which require lifetime use, time-restricted eating is a simple lifestyle change that does not cause side effects and can be maintained indefinitely,” one doctor explained. 

The FTC alleges that pharmacy benefit managers have set up a system where they get rich, while patients are forced to pay rising insulin costs. The agency also called out drug manufacturers such as Eli Lilly, Sanofi and Novo Nordisk, saying their own actions have raised serious concerns.

Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, explains some of the key technology and treatment trends he has his eyes on.